Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy
ELK CITY, Idaho, April 26, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating an unexpected synergy between its inducible pluripotent stem cell (StemVacs-V iPSC) derived immunotherapy product with low dose cyclophosphamide in evoking potent immune mediated cancer regression. In a series of experiments, the Company demonstrated that its previously announced stem cell derived tumor endothelial-like cell vaccine 1 enabled non-toxic doses of cyclophosphamide, an established chemotherapeutic agent, to induce significan...